BiotechTube
Home/Adaptimmune Therapeutics/Garry Menzel, Ph.D.
GM

Garry Menzel, Ph.D.

Non-Executive Director

Adaptimmune Therapeutics

Therapeutic Areas

Oncology

Adaptimmune Therapeutics Pipeline

DrugIndicationPhase
ADP-600PRAME-expressing cancers (synovial sarcoma, breast, NSCLC, gastroesophageal, melanoma, endometrial, ovarian, head & neck)Indication Enabling
ADP-520CD70-expressing cancers (hematological malignancies, AML, lymphoma, RCC)Indication Enabling

Leadership Team at Adaptimmune Therapeutics

LM
Lawrence M. Alleva
Chairman and Non-Executive Director
C(
Christopher (Chris) Hill
Chief Executive Officer and Chief Financial Officer
View full Adaptimmune Therapeutics profile